Lupin Shares Phase 1 Data on LNP8701 at the ASCO Annual Meeting 2026
MUMBAI, India and NAPLES, Fla. and CHICAGO, May 28, 2026 /PRNewswire/ -- Lupin Limited (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) announced that results from its Phase 1a trial evaluating LNP8701, a novel SOS1 inhibitor, have been accepted for publication at...
MUMBAI, India and NAPLES, Fla. and CHICAGO, May 28, 2026 /PRNewswire/ -- Lupin Limited (Lupin) (BSE: 500257) (NSE: LUPIN) (REUTERS: LUPIN.BO) (BLOOMBERG: LPCIN) announced that results from its Phase 1a trial evaluating LNP8701, a novel SOS1 inhibitor, have been accepted for publication at...
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.